Windtree Therapeutics, Inc. (WINT)

OTCMKTS · Delayed Price · Currency is USD

0.0139

-0.0011 (-7.33%)

At close: Mar 5, 2026

Windtree Therapeutics Employees

Windtree Therapeutics had 14 employees as of December 31, 2024. The number of employees decreased by 6 or -30.00% compared to the previous year.

Employees

14

Change

-6

Growth

-30.00%

Revenue / Employee

n/a

Profits / Employee

-$3,487,929

Market Cap

595.61K

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	14	-6	-30.00%
Dec 31, 2022	20	-13	-39.39%
Dec 31, 2021	33	2	6.45%
Dec 31, 2020	31	-1	-3.13%
Dec 31, 2019	32	-1	-3.03%
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro
Dec 31, 2016	Pro	Pro	Pro
Dec 31, 2015	Pro	Pro	Pro
Dec 31, 2014	Pro	Pro	Pro

Related Stocks

Company Name	Employees
Hepion Pharmaceuticals	22
Altamira Therapeutics	11
Actavia Life Sciences	1
Bio-Path Holdings	10
Innovation Pharmaceuticals	4
Lipella Pharmaceuticals	7
Scorpius Holdings	91

Employee Rankings

Windtree Therapeutics News

4 months ago - Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company - GlobeNewsWire
7 months ago - Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025 - GlobeNewsWire
7 months ago - Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption - GlobeNewsWire
8 months ago - Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy - GlobeNewsWire
8 months ago - Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions - GlobeNewsWire
8 months ago - Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure - GlobeNewsWire
9 months ago - Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel - GlobeNewsWire
10 months ago - Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 - GlobeNewsWire